Detalhe da pesquisa
1.
Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development.
J Immunother Cancer
; 11(7)2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37487665
2.
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies.
J Immunother Cancer
; 11(3)2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36918225
3.
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
J Immunother Cancer
; 11(3)2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37001909
4.
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.
J Immunother Cancer
; 8(1)2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32238470
5.
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.
J Natl Cancer Inst
; 111(2): 118-128, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30561713
6.
Rapid androgen cycling as treatment for patients with prostate cancer.
Clin Cancer Res
; 12(24): 7414-21, 2006 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17189414
7.
The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience.
Pharmacol Ther
; 148: 132-53, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25476108
8.
DNA vaccines: Vector design, delivery, and antigen presentation.
J Cell Biochem
; 72(S30-31): 304-311, 1998.
Artigo
em Inglês
| MEDLINE | ID: mdl-29345830